2023-01-042023-01-042017Dilektaşlı, A. G. vd. (2017). ''Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization''. International Journal of COPD, 12, 199-208.1178-2005https://www.dovepress.com/getfile.php?fileID=34330https://doi.org/10.2147/COPD.S118424http://hdl.handle.net/11452/30261Introduction: Chemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization. Materials and methods: Clinically stable COPD patients and participants with smoking history but normal spirometry (NSp) were recruited for the study. Modified Medical Research Council Dyspnea Scale, COPD Assessment Test, spirometry, and 6-min walking test were performed. Serum CCL-18 levels were measured with a commercial ELISA Kit. Results: Sixty COPD patients and 20 NSp patients were recruited. Serum CCL-18 levels were higher in COPD patients than those in NSp patients (169 vs 94 ng/mL, P, 0.0001). CCL-18 level was significantly correlated with the number of exacerbations (r=0.30, P=0.026), although a difference in CCL-18 values between infrequent and frequent exacerbator COPD (168 vs 196 ng/mL) subgroups did not achieve statistical significance (P=0.09). Serum CCL-18 levels were significantly higher in COPD patients who had experienced at least one exacerbation during the previous 12 months. Overall, ROC analysis revealed that a serum CCL-18 level of 181.71 ng/mL could differentiate COPD patients with hospitalized exacerbations from those who were not hospitalized with a 88% sensitivity and 88.2% specificity (area under curve: 0.92). Serum CCL-18 level had a strong correlation with the frequency of exacerbations requiring hospitalization (r=0.68, P, 0.0001) and was found to be an independent risk factor for hospitalized exacerbations in the multivariable analysis. Conclusion: CCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores.eninfo:eu-repo/semantics/openAccessRespiratory systemCOPDFrequent exacerbatorHospitalized exacerbationPARC/(CCL-18)Obstructive pulmonary-diseaseSystemic inflammationLung-functionBiomarkersFrequencyCCL18MacrophagesValidationPhenotypesDyspneaAgedBiomarkersCase-control studiesChemokines, CCCross-sectional studiesDisease progressionEnzyme-linked immunosorbent assayExercise toleranceFemaleHospitalizationHumansLungMaleMiddle agedPhenotypePulmonary disease, chronic obstructiveRisk factorsSpirometrySurveys and questionnairesUp-regulationWalk testArticle0003912005000012-s2.0-850094658931992081228115842Respiratory systemUndifferentiated Connective Tissue Diseases; Adrenal Cortex Hormone; Global InitiativesBiological markerCC chemokine ligand 18ChemokineUnclassified drugBeta chemokineBiological markerCCL18 protein, humanAdultAgedArea under the curveArticleChronic obstructive lung diseaseControlled studyCOPD assessment testDiagnostic test accuracy studyDisease associationDisease exacerbationDisease severityELISA kitFemaleHospitalizationHumanMajor clinical studyMaleModified medical research council dyspnea scalePhenotypePredictive valueProtein blood levelReceiver operating characteristicRespiratory tract disease assessmentRisk factorSensitivity and specificitySix minute walk testSpirometryUpregulationBloodCase control studyCross-sectional studyDisease courseEnzyme linked immunosorbent assayExercise toleranceLungMiddle agedPathophysiologyPulmonary disease, chronic obstructiveQuestionnaireRisk factorWalk test